| 摘要 |
The present invention provides methods of promoting synthesis of nitric oxid e or endothelium-derived relaxing factor (EDRF) in hypoxic mammalian tissues b y administering at least one N-hydroxyguanidine compound that is a substrate o f nitric oxide synthase and at least one thromboxane inhibitor, and, optionall y, one or more vasoactive agents. The present invention also provides methods o f promoting vasorelaxation and treating sexual dysfunctions in patients by administering at least one N-hydroxyguanidine compounds that is a substrate for nitric oxide synthase and at least one thromboxane inhibitor, and, optionally, one or more vasoactive agents. The present invention also provid es methods for treating clinical conditions resulting from hypoxic conditions such as pulmonary disease, cardiovascular disorders, circulatory hypoxia, specific organ hypoxia, localized hypoxia, edema, central nervous system disorders, memory loss, or arterial disease. The present invention also provides methods for treating clinical conditions resulting from a high leve l of arginase activity, such as, heart disease, systemic hypertension, pulmona ry hypertension, sexual dysfunction, autoimmune disease, chronic renal failure and cerebral vasospasm. The present invention also provides methods for treating clinical conditions associated with a deficient nitric oxide pathwa y by the administration of at least one N-hydroxyguanidine compound and at lea st one thromboxane inhibitor, and, optionally, one or more vasoactive agents. T he present invention also provides pharmaceutical compositions comprising at least one N-hydroxyguanidine compound and at least one thromboxane inhibitor , and, optionally, one or more vasoactive agents.
|
